Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Thyroid cancer | R-HSA-9700206 | map05216 | ceftazidime | 5280953 | drug-path |
Chronic myeloid leukemia | R-HSA-9680350 | map05220 | ceftazidime | 5280953 | drug-path |
Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | adrenosterone | 5951 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | adrenosterone | 5951 | drug-path |
Non-small cell lung cancer | R-HSA-5619066 | map05223 | adrenosterone | 5951 | drug-path |
ECM-receptor interaction | R-HSA-373711 | map04512 | adrenosterone | 5951 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | adrenosterone | 5951 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | adrenosterone | 5951 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | adrenosterone | 5951 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | adrenosterone | 5951 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | adrenosterone | 5951 | drug-path |
Asthma | R-HSA-444620 | map05310 | adrenosterone | 5951 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | adrenosterone | 5951 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | adrenosterone | 5951 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | oxyphenbutazone | 4641 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | oxyphenbutazone | 4641 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | oxyphenbutazone | 4641 | drug-path |
Homologous recombination | R-HSA-5685942 | map03440 | oxyphenbutazone | 4641 | drug-path |
Shigellosis | 0 | map05131 | oxyphenbutazone | 4641 | drug-path |
Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | oxyphenbutazone | 4641 | drug-path |